Evidence map›Paper›PMID 25368993›Full record

ArticlePloS one2014

Regulation of RAB5C is important for the growth inhibitory effects of MiR-509 in human precursor-B acute lymphoblastic leukemia.

Yee Sun Tan, MinJung Kim, Tami J Kingsbury, Curt I Civin, Wen-Chih Cheng

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. TheAutophagy · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yee Sun TanCenter for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
MinJung KimCenter for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Tami J KingsburyCenter for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Curt I CivinCenter for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Wen-Chih ChengCenter for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
University of Maryland, Baltimore · USU-M Rogel Cancer Center

Funding

THERAPEUTIC USE OF STEM CELLSP01CA070970 · NCI · JOHNS HOPKINS UNIVERSITY · PI CIVIN, CURT I · 1998 to 2012
$23.7M
NCI NIH HHS P01 CA070970NCI NIH HHS P01CA70970
6 · The paper itself

Abstract

MicroRNAs (miRs) regulate essentially all cellular processes, but few miRs are known to inhibit growth of precursor-B acute lymphoblastic leukemias (B-ALLs). We identified miR-509 via a human genome-wide gain-of-function screen for miRs that inhibit growth of the NALM6 human B-ALL cell line. MiR-509-mediated inhibition of NALM6 growth was confirmed by 3 independent assays. Enforced miR-509 expression inhibited 2 of 2 additional B-ALL cell lines tested, but not 3 non-B-ALL leukemia cell lines. MiR-509-transduced NALM6 cells had reduced numbers of actively proliferating cells and increased numbers of cells undergoing apoptosis. Using miR target prediction algorithms and a filtering strategy, RAB5C was predicted as a potentially relevant target of miR-509. Enforced miR-509 expression in NALM6 cells reduced RAB5C mRNA and protein levels, and RAB5C was demonstrated to be a direct target of miR-509. Knockdown of RAB5C in NALM6 cells recapitulated the growth inhibitory effects of miR-509. Co-expression of the RAB5C open reading frame without its 3' untranslated region (3'UTR) blocked the growth-inhibitory effect mediated by miR-509. These findings establish RAB5C as a target of miR-509 and an important regulator of B-ALL cell growth with potential as a therapeutic target.

Indexed as

Gene Expression Regulation, NeoplasticCell Line, TumorCell ProliferationHumansMicroRNAsPrecursor B-Cell Lymphoblastic Leukemia-Lymphomarab5 GTP-Binding ProteinsRNA, MessengerS Phase Cell Cycle CheckpointsMicroRNAsMIRN509 microRNA, humanRAB5C protein, humanrab5 GTP-Binding ProteinsRNA, Messenger

Identifiers

PMID25368993
PMCPMC4219775
OpenAlexW1970460208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.